2006
DOI: 10.1016/j.ejphar.2005.12.058
|View full text |Cite
|
Sign up to set email alerts
|

Prostanoids as pharmacological targets in COPD and asthma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
62
0
2

Year Published

2008
2008
2020
2020

Publication Types

Select...
7
2
1

Relationship

0
10

Authors

Journals

citations
Cited by 84 publications
(64 citation statements)
references
References 136 publications
0
62
0
2
Order By: Relevance
“…It is well accepted that arachidonic acid metabolites (prostanoids and isoprostanes) play a key role in the pathophysiology of diseases associated with infl ammation, platelet aggregation and vasoconstriction/relaxation. Consequently, the inhibition of their production and/or the blockade of their respective receptors have greatly contributed to the understanding of their mode of action and their involvement in the pathology, and have also demonstrated clinical effectiveness in bronchial asthmas (Rolin et al, 2006).…”
Section: Introductionmentioning
confidence: 99%
“…It is well accepted that arachidonic acid metabolites (prostanoids and isoprostanes) play a key role in the pathophysiology of diseases associated with infl ammation, platelet aggregation and vasoconstriction/relaxation. Consequently, the inhibition of their production and/or the blockade of their respective receptors have greatly contributed to the understanding of their mode of action and their involvement in the pathology, and have also demonstrated clinical effectiveness in bronchial asthmas (Rolin et al, 2006).…”
Section: Introductionmentioning
confidence: 99%
“…Nevertheless, even recently the TP antagonist terutroban was shown to exhibit superior antithrombotic activity compared with as- PROSTAGLANDIN RECEPTORS pirin in humans (Bal Dit Sollier et al, 2009). Another early indication for TP antagonists was asthma, which met with some clinical success, albeit limited (Rolin et al, 2006;Jones et al, 2009). Other early indications do not seem to have met with any clinical success.…”
mentioning
confidence: 99%
“…• Après une stimulation allergique, la production d'IgE active les mastocytes qui sécrétent environ 50 média-teurs chimiques différents dont la PGD2, qui vont tous contribuer à la réponse allergique [20]. La PGD2 induit la production d'histamine puis une vasodilatation dans la muqueuse nasale, une bronchoconstriction et le recrutement et l'activation des lymphocytes Th2 et des éosinophiles via les récepteurs DP1, TP et CRTH2 respectivement [21,22].…”
Section: Les Rôles De La Prostaglandine D2unclassified